Efficacy, nephrotoxicity and ototoxicity of aminoglycosides, mathematically modelled for modelling-supported therapeutic drug monitoring.
暂无分享,去创建一个
Cees Neef | S. V. van Gils | Sander Croes | Arjen H. Koop | Stephan A. van Gils | C. Neef | A. Koop | S. Croes
[1] M. Falagas,et al. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. , 2005, The Lancet. Infectious diseases.
[2] D. Nicolau,et al. Extended interval aminoglycoside dosing: from concept to clinic. , 2002, International journal of antimicrobial agents.
[3] Cees Neef,et al. Analogy between temperature-dependent and concentration-dependent bacterial killing , 2002, Comput. Biol. Medicine.
[4] J. Bartlett,et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] L. Rybak,et al. Drug ototoxicity. , 1986, Annual review of pharmacology and toxicology.
[6] R. Jelliffe,et al. Aminoglycoside Dosages and Nephrotoxicity , 2003, Clinical pharmacokinetics.
[7] Y. Almog,et al. Pharmacokinetic dosing of aminoglycosides: a controlled trial. , 2003, The American journal of medicine.
[8] D. Leehey,et al. Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy. , 1993, Journal of the American Society of Nephrology : JASN.
[9] T. Murakami,et al. Targeted prevention of renal accumulation and toxicity of gentamicin by aminoglycoside binding receptor antagonists. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[10] M. D. de Broe,et al. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. , 1986, The Journal of pharmacology and experimental therapeutics.
[11] A. Zavascki. Continuous intravenous administration of antibiotics. , 2006, The Lancet. Infectious diseases.
[12] R. Jelliffe,et al. Aminoglycoside Nephrotoxicity: Modeling, Simulation, and Control , 2003, Antimicrobial Agents and Chemotherapy.
[13] N. Benowitz,et al. Once-daily dosing of aminoglycosides: how much monitoring is truly required? , 2003, The American journal of medicine.
[14] C H Nightingale,et al. A pharmacodynamic model for the activity of antibiotics against microorganisms under nonsaturable conditions. , 1986, Journal of pharmaceutical sciences.
[15] C H Nightingale,et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients , 1995, Antimicrobial agents and chemotherapy.
[16] X. Barbaut,et al. Comparisons between Antimicrobial Pharmacodynamic Indices and Bacterial Killing as Described by Using the Zhi Model , 1998, Antimicrobial Agents and Chemotherapy.
[17] G. Drusano,et al. Prospective Evaluation of the Effect of an Aminoglycoside Dosing Regimen on Rates of Observed Nephrotoxicity and Ototoxicity , 1999, Antimicrobial Agents and Chemotherapy.
[18] H. Neu,et al. The Aminoglycosides: Microbiology, Clinical Use, and Toxicology , 1982 .
[19] F. O. Black,et al. Permanent Gentamicin Vestibulotoxicity , 2004, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.
[20] G. Mulder,et al. Isolated proximal tubular cells from rat kidney as an in vitro model for studies on nephrotoxicity. I. An improved method for preparation of proximal tubular cells and their functional characterization by alpha-methylglucose uptake. , 1989, Toxicology and applied pharmacology.
[21] M. D. de Broe,et al. Renal cortical uptake kinetics of gentamicin in rats with impaired renal function. , 1986, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[22] R. Jelliffe,et al. Estimation of creatinine clearance from changing serum-creatinine levels. , 1971, Lancet.
[23] M. D. de Broe,et al. The effect of dosing strategy on kidney cortical accumulation of aminoglycosides in rats. , 1986, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[24] A. Nafziger,et al. Application of Bayes Theorem to Aminoglycoside‐Associated Nephrotoxicity: Comparison of Extended‐Interval Dosing, Individualized Pharmacokinetic Monitoring, and Multiple‐Daily Dosing , 2004, Journal of clinical pharmacology.
[25] A. Vinks,et al. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics. , 1997, The Journal of antimicrobial chemotherapy.
[26] P. Tulkens,et al. Aminoglycosides: Nephrotoxicity , 1999, Antimicrobial Agents and Chemotherapy.
[27] J. Schacht,et al. Aspirin attenuates gentamicin ototoxicity: From the laboratory to the clinic , 2007, Hearing Research.
[28] A. Nunnery. Antimicrobial therapy of gram-negative infections. , 1971, Postgraduate medicine.
[29] Wilhelm Huisinga,et al. Physiologically based pharmacokinetic modelling: a sub-compartmentalized model of tissue distribution , 2007, Journal of Pharmacokinetics and Pharmacodynamics.
[30] E. Kuijper,et al. Once versus thrice daily gentamicin in patients with serious infections , 1993, The Lancet.
[31] A. Vinks. The application of population pharmacokinetic modeling to individualized antibiotic therapy. , 2002, International journal of antimicrobial agents.
[32] M. D. de Broe,et al. Aminoglycoside nephrotoxicity: mechanism and prevention. , 1989, Advances in experimental medicine and biology.
[33] Frieder Keller,et al. Mechanism-based pharmacokinetic–pharmacodynamic modeling of antimicrobial drug effects , 2007, Journal of Pharmacokinetics and Pharmacodynamics.
[34] F. Hoek,et al. Circadian rhythm of glomerular filtration rate in normal individuals. , 1989, Clinical science.